Hørsholm,
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company's website.
Join us at Redeye's thematic event, Fight Cancer, in
ExpreS2ion Senior Vice President of R&D and Technology Dr. Max Søgaard is invited to present at the 16th Annual Bio Innovation Leaders Summit, to be held at the
Certified Adviser
For further information about ExpreS2ion
Bent U. Frandsen, CEO
E-mail: investor@expres2ionbio.com
About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2(TM), for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2(TM), includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with
https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-to-present-in-redeye-fight-cancer-event-and-the-bio-innovation-leaders-summit,c3913243
https://mb.cision.com/Main/14402/3913243/2553904.pdf
(c) 2024 Cision. All rights reserved., source